S'abonner

The transcription factors GATA2 and microphthalmia-associated transcription factor regulate Hdc gene expression in mast cells and are required for IgE/mast cell–mediated anaphylaxis - 05/10/18

Doi : 10.1016/j.jaci.2017.10.043 
Yapeng Li, PhD a, Bing Liu, MD a, b, Laura Harmacek, PhD c, Zijie Long, PhD a, d, Jinyi Liang, BS a, e, Kara Lukin, PhD a, Sonia M. Leach, PhD a, c, Brian O'Connor, PhD a, c, Anthony N. Gerber, MD, PhD a, f, James Hagman, PhD a, g, Axel Roers, MD h, Fred D. Finkelman, MD i, j, Hua Huang, MD, PhD a, g,
a Department of Biomedical Research, National Jewish Health, Denver, Colo 
c Center for Genes, Environment and Health, National Jewish Health, Denver, Colo 
f Department of Medicine, National Jewish Health, Denver, Colo 
b Department of Respiratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China 
d Department of Hematology, The Third Affiliated Hospital, Institute of Hematology, Sun Yat-sen University, Guangzhou, China 
e Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China 
g Department of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Colo 
h Institute for Immunology, Technische Universit ät Dresden, Dresden, Germany 
i Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 
j Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 

Corresponding author: Hua Huang, MD, PhD, Department of Biomedical Research, National Jewish Health, 1400 Jackson St, Denver, CO 80206.Department of Biomedical ResearchNational Jewish Health1400 Jackson StDenverCO80206

Abstract

Background

Histamine is a critical mediator of IgE/mast cell–mediated anaphylaxis. Histamine is synthesized by decarboxylating the amino acid histidine, a reaction catalyzed by the histidine decarboxylase (Hdc) gene–encoded enzyme HDC. However, regulation of the Hdc gene in mast cells is poorly understood.

Objective

We sought to investigate the in vivo regulation of IgE/mast cell–mediated anaphylaxis by the transcription factors GATA2 and microphthalmia-associated transcription factor (MITF) and the mechanisms by which GATA2 and MITF regulate Hdc gene expression in mouse and human mast cells.

Methods

Mice deficient in the transcription factors Gata2, aryl hydrocarbon receptor (Ahr), aryl hydrocarbon receptor repressor (Ahrr), or basic helix-loop-helix family member E40 (Bhlhe40) were assessed for anaphylactic reactions. Chromatin immunoprecipitation sequencing analysis identified putative Hdc enhancers. Luciferase reporter transcription assay confirmed enhancer activities of putative enhancers in the Hdc gene. The short hairpin RNA knockdown approach was used to determine the role of MITF in regulating mouse and human HDC gene expression.

Results

Connective tissue mast cell–specific Gata2-deficient mice did not have IgE/mast cell-mediated anaphylaxis. GATA2 induced the expression of Mitf, Ahr, Ahrr, and Bhlhe40 in mast cells. MITF, but not AHR, AHRR, or BHLHE40, was required for anaphylaxis. MITF bound to an enhancer located 8.8 kb upstream of the transcription start site of the Hdc gene and directed enhancer activity. MITF overexpression largely restored Hdc gene expression in the Gata2-deficient mast cells. In the human mast cell line LAD2, MITF was required for the HDC gene expression and histamine synthesis.

Conclusion

The transcription factors GATA2 and MITF regulate Hdc gene expression in mast cells and are required for IgE/mast cell–mediated anaphylaxis.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Mast cell, connective tissue mast cell, GATA2, microphthalmia-associated transcription factor, histidine decarboxylase, enhancer, anaphylaxis, histamine synthesis

Abbreviations used : AHR, AHRR, BHLHE40, BMMC, ChIP-seq, CTMC, HDC, H3K27Ac, H3K4me1, MITF, MMCP-1, PCA, PCMC, pre-BMP, PSA, qPCR, shRNA, TNP, YFP


Plan


 Supported by grants from the National Institutes of Health (R01AI107022 and RO1AI083986 to H.H., R01 AI098417 to J.H., and R01AI113162 to F.D.F.), funds provided by the China Scholarship Council (201606385033 to Z.L. and 201406270087 to B.L.), and funds provided by Sun Yet-Sen University (to J.L.).
 Disclosure of potential conflict of interest: Y. Li and H. Huang have received grants from the National Institutes of Health (NIH; R01AI107022 and RO1AI083986). B. Liu has received grants from the NIH (R01AI107022 and RO1AI083986) and the China Scholarship Council (201406270087). Z. Long has received grants from the NIH (R01AI107022 and RO1AI083986) and the China Scholarship Council (201606385033). J. Liang has received grants from the NIH (R01AI107022 and RO1AI083986) and Sun Yat-Sen University. F. D. Finkelman has consultant arrangements with Vedanta Bioscience; is employed by the University of Cincinnati; has received grants from the National Institutes of Health and Food Allergy Research & Education; and has 3 patents from the University of Cincinnati and the Cincinnati Children's Hospital Medical Center. The rest of the authors declare that they have no relevant conflicts of interest.


© 2017  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 142 - N° 4

P. 1173-1184 - octobre 2018 Retour au numéro
Article précédent Article précédent
  • The vascular endothelial specific IL-4 receptor alpha–ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions
  • Amnah Yamani, David Wu, Lisa Waggoner, Taeko Noah, Anthony J. Koleske, Fred Finkelman, Simon P. Hogan
| Article suivant Article suivant
  • A bispecific antibody strategy to target multiple type 2 cytokines in asthma
  • Marie Godar, Kim Deswarte, Karl Vergote, Michael Saunders, Hans de Haard, Hamida Hammad, Christophe Blanchetot, Bart N. Lambrecht

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.